More good news! In addition to last week’s announcement of very high (90%) COVID-19 vaccine efficacy emerging from the first interim analysis of a phase 3 trial [1], we received word that a second vaccine had similar initial efficacy at 94.5%.[2] Both of these candidates use an mRNA platform, a novel approach to human vaccines. Th...